The state-of-the-art inpatient hospital will increase adult patient capacity. It will also create flexibility to incorporate the innovations and technology in cancer care that Dana-Farber’s and BIDMC’s researchers and clinicians are developing every day. Located adjacent to existing Dana-Farber and BIDMC facilities in Longwood, the proposed new cancer hospital will support both seamless patient care and continued focus on research initiatives.

Pending regulatory approvals, it will take several years to implement the cancer collaboration and construct the new cancer hospital. Dana-Farber’s current affiliation with Brigham and Women’s Hospital for inpatient and surgical care, long-renowned for its positive outcomes and high-quality patient care, will continue through the transition. BIDMC’s nationally recognized independent oncology programs will also continue until the new collaboration is in place.


Outpatient oncology care at Dana-Farber’s existing locations in Boston, Chestnut Hill and other regional campuses will not be interrupted. Likewise, the cancer institute’s partnership for pediatric cancer care with Boston Children’s Hospital will not change. Beth Israel Lahey Health will also continue to invest in advancing cancer services at BIDMC and at its other hospitals, fulfilling their commitment to provide access to extraordinary care in community settings.

Back to HCB News

Business Affairs Homepage